

Row No	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
1	16/LO/0422	30498	A Phase I trial of oral CCT245737	Number Agreed	5	5	Date Agreed	03/05/2019	5	03/05/2019	5	Recruitment Finished
2	16/SC/0494	30254	Triple vs dual therapy in inadequately controlled asthma	Not Available / Not Agreed			Date Agreed	14/06/2019	0	14/06/2019	0	Recruitment Finished
3	16/NE/0384	30561	PARADISE-MI	Number Agreed	5	5	Date Agreed	13/03/2020	16	13/03/2020	16	Recruitment Finished
4	17/LO/0402	30944	IMmotion010	Number Agreed	3	3	Date Agreed	12/11/2019	3	12/11/2019	3	Recruitment Finished
5	15/NE/0350	16863	RESP 3213 (Lung Volume Reduction Coil)	Number Agreed	15	15	Date Agreed	12/11/2019	16	12/11/2019	16	Recruitment Finished
6	17/EM/0059	34435	1245.121 EMPEROR-Reduced Study	Number Agreed	7	7	Date Agreed	30/08/2019	7	30/08/2019	7	Recruitment Finished
7	17/LO/0041	33958	CardioMEMS HF System OUS Post Approval Study	Number Agreed	10	10	Date Agreed	31/07/2019	16	31/07/2019	16	Recruitment Finished
8	17/EE/0177	33729	BOSTON: Open-label Study of SVD versus VD in patients with RRMM	Number Agreed	5	5	Date Agreed	12/11/2019	5	12/11/2019	5	Recruitment Finished
9	18/LO/0712	36486	MK-7264 Phase 3 study in adult participants with chronic cough (PN027)	Number Agreed	5	5	Date Agreed	07/05/2019	12	07/05/2019	12	Recruitment Finished
10	19/NI/0037	36650	Protocol 16-021 ? Pediatric PK	Number Agreed	1	1	Date Agreed	24/09/2019	1	24/09/2019	1	Recruitment Finished
11	18/LO/1301	39511	VIVO Accuracy study	Number Agreed	6	6	Date Agreed	14/06/2019	6	14/06/2019	6	Recruitment Finished
12	18/EM/0326	38837	Action of Tezepelumab on airway inflammation in moderate-severe asthma	Number Agreed	8	8	Date Agreed	13/02/2020	10	13/02/2020	10	Recruitment Finished
13	18/EM/0336	39357	CEPHEUS	Number Agreed	3	3	Date Agreed	19/07/2019	3	19/07/2019	3	Recruitment Finished
14	12/NW/0694	11062	MCRN150 (A0221047)	Number Agreed	2	2	Date Agreed	07/11/2019	0	07/11/2019	0	Recruitment Finished
15	13/NE/0005	14518	CCRN 2040 (Heart failure)	Number Agreed	5	5	Date Agreed	31/05/2019	4	31/05/2019	4	Recruitment Finished
16	16/NW/0041	19285	CANC - 4492 - SOLAR-1	Number Agreed	8	8	Date Agreed	26/02/2020	2	26/02/2020	2	Recruitment Finished
17	16/EE/0196	31253	CHIL 5025 A 24 Week Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapgliflozin	Number Agreed	2	2	Date Agreed	24/09/2019	1	24/09/2019	1	Recruitment Finished
18	16/EE/0183	20107	MUSC 3998	Number Agreed	1	1	Date Agreed	12/11/2019	0	12/11/2019	0	Recruitment Finished
19	17/NE/0092	31054	B5091007 - C.Difficile infection-9002/0359-Pfizer	Number Agreed	18	18	Date Agreed	12/11/2019	7	12/11/2019	7	Recruitment Finished
20	16/EE/0463	31440	CompLEEment-1	Number Agreed	5	5	Date Agreed	30/10/2019	2	30/10/2019	2	Recruitment Finished
21	16/NW/0620	32953	Pro2tect-Correction	Number Agreed	2	2	Date Agreed	12/11/2019	0	12/11/2019	0	Recruitment Finished
22	16/NW/0621	32957	Pro2tect-Conversion	Number Agreed	2	2	Date Agreed	30/08/2019	0	30/08/2019	0	Recruitment Finished
23	17/EM/0058	33789	1245.110 EMPEROR-Preserved Study	Number Agreed	6	6	Date Agreed	12/12/2019	1	12/12/2019	1	Recruitment Finished
24	17/SW/0221	33890	(CAIN457K2340) Secukinumab compared with GP2017 in Active AS	Number Agreed	4	4	Date Agreed	16/05/2019	1	16/05/2019	1	Recruitment Finished
25	18/LO/0416	34807	Evaluation of Avelumab combined with Talazoparib in solid tumours	Number Agreed	5	5	Date Agreed	07/10/2019	3	07/10/2019	3	Recruitment Finished

Row No	REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
26	18/EE/0092	37134	Study to evaluate the safety & efficacy of 13 weeks of SARM GSK2881078	Number Agreed	8	8	Date Agreed	24/06/2019	7	24/06/2019	7	Recruitment Finished
27	17/NW/0546	35527	C16029: Phase 2/3 Randomized, Open-Label Study in Multiple Myeloma	Number Agreed	3	3	Date Agreed	11/09/2019	0	11/09/2019	0	Recruitment Finished
28	17/YH/0432	35847	GSK3772847 in participants with Asthma with AFAD	Number Agreed	3	3	Date Agreed	30/06/2019	2	30/06/2019	2	Recruitment Finished
29	17/LO/1672	36044	MDS Clinical Utility Study OMS002-1	Number Agreed	100	100	Date Agreed	12/11/2019	68	12/11/2019	68	Recruitment Finished
30	18/YH/0055	37480	Jazz JZP963-201	Number Agreed	3	3	Date Agreed	22/10/2019	1	22/10/2019	1	Recruitment Finished
31	18/SC/0037	37178	RO5541007 in lymphoma	Number Agreed	3	3	Date Agreed	03/06/2019	2	03/06/2019	2	Recruitment Finished
32	18/WA/0262	36985	CL140FSGS	Number Agreed	1	1	Date Agreed	18/07/2019	0	18/07/2019	0	Recruitment Finished
33	18/EM/0217	39008	ANTHEM	Number Agreed	4	4	Date Agreed	05/11/2019	0	05/11/2019	0	Withdrawn By Sponsor
34	18/EE/0197	38614	Phase 2 study of the Safety and Efficacy of ADCT-402 on DLBCL Patients	Number Agreed	5	5	Date Agreed	28/08/2019	2	28/08/2019	2	Recruitment Finished
35	18/EE/0296	39536	Comparison of AZD9977 with Spironolactone in Heart Failure	Number Agreed	3	3	Date Agreed	16/03/2020	1	16/03/2020	1	Recruitment Finished
36	19/EE/0014	40988	IXchange	Number Agreed	2	2	Date Agreed	10/12/2019	0	10/12/2019	0	Recruitment Finished
37	19/EE/0200	41811	Investigating tirzepatide versus semaglutide in Type 2 Diabetes	Number Agreed	8	8	Date Agreed	17/01/2020	1	17/01/2020	1	Recruitment Finished